Dianthus Therapeutics, Inc. DNTH 深 沪
等待开盘 05-12 09:30:00 美东时间
86.165
-0.595
-0.69%
华盛通- 最 高91.81
- 今 开86.62
- 成交量 13.10万股
- 最 低 83.56
- 昨 收 86.76
- 总市值 0
- 52周最高 96.5033
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 16.635
- 委 比 76.26%
- 总股本 --
- 历史最高 96.5033
- 量 比 0.32
- 振 幅 9.51%
- 历史最低 0.321
- 每 手 1
- 风险率 21.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Wall Street analysts upgraded CRWD, ALEC, RIVN, SEDG, and DNTH. See what other analysts say about these stocks. Consider buying CRWD.
03-10 20:32
Dianthus Therapeutics Announces Proposed $400M Public Offering
Dianthus announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase
03-10 04:03
Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism
Dianthus Therapeutics shares jump after early success in a Phase 3 trial for CIDP treatment claseprubart, signaling potential progress toward approval.
03-09 21:22
Dianthus Therapeutics Earnings Review: Q4 Summary
Dianthus Therapeutics (NASDAQ:DNTH) announced its Q4 earnings on Monday, March ...
03-09 19:36
【晨观方正】创新药多个BD落地映证产业趋势持续 / 香港楼市是怎样止跌回稳的？20251021
今天是2025年10月21日星期二，农历八月二十九。每一个秋日的清晨，方正研究向您提供及时新鲜的研究观点，秉持“独立、客观、理性、真诚”的理念，珍重您的信任，保...
2025-10-21 08:33
一天三个BD，创新药再掀狂潮！翰森制药逆市涨近4%，BD总额超15.3亿美元！港股通创新药ETF(159570)资金近20日净流入超29亿元！
今日（10.17），在连续两日反攻后，港股通创新药ETF（159570）回调一度超1%，现跌幅收窄至0.38%，盘中成交额快速突破8.6亿元！资金面上，近20日...
2025-10-17 11:18
10亿美元出海，来自今年最火IPO之一
（来源：动脉新医药） 10月16日晚，南京维立志博与Dianthus Therapeutics宣布已就DNTH212（LBL-047）达成独家许可协议。双方达成...
2025-10-17 08:00
维立志博-B(09887)就LBL-047与DIANTHUS签订全球独家许可协议
维立志博-B(09887)发布公告，于2025年10月16日，本公司与Dianthus Therapeutics, Inc.(Dianthus，纳斯达克代码：...
2025-10-16 20:55
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
Dianthus Therapeutics announced its participation in the Jefferies Global Healthcare Conference, with CEO Marino Garcia to hold a fireside chat and investor meetings. The company focuses on developing advanced antibody therapies for severe autoimmune diseases.
2025-05-29 11:00
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
Dianthus Therapeutics appoints Simon Read, Ph.D., to its Board of Directors, while Lonnie Moulder steps down. Dr. Read, a seasoned biopharmaceutical leader with over 30 years of experience, previously founded and led Mariana Oncology and Ra Pharma. Dianthus is advancing innovative antibody complement therapeutics for severe autoimmune diseases, with three clinical programs underway, including DNTH103.
2025-05-22 20:10
